With the S&P 500 Shiller CAPE ratio above 41 and AI high flyers like Nvidia, Sandisk, and Micron Technology grabbing headlines, many investors are starting to look past crowded growth stories and toward areas that might offer a steadier ride. Healthcare sector stocks are drawing fresh attention as some investors rotate toward businesses tied to essential services while inflation, geopolitical tensions, and a new Federal Reserve chair keep volatility elevated. This article breaks down 3 larger healthcare stocks from our screener that are closely exposed to these market shifts and that may either benefit from or be challenged by today’s conditions.

BeOne Medicines (ONC)

Overview: BeOne Medicines is a Basel based oncology company that develops and commercializes cancer treatments worldwide, with a portfolio that includes BTK inhibitors like BRUKINSA, immunotherapies such as TEVIMBRA, and a broad pipeline of targeted therapies across blood cancers and solid tumors.

Operations: BeOne Medicines generates US$5.7b from pharmaceutical products, with revenue concentrated in the United States at about US$3.1b, followed by China at roughly US$1.8b, Europe at about US$0.7b, and the rest of the world at around US$0.2b.

Market Cap: US$34.3b

BeOne Medicines stands out in this healthcare screen because it combines blockbuster commercial drugs such as BRUKINSA and TEVIMBRA with a deep late stage pipeline that is already producing encouraging Phase 3 data in multiple cancers. Recent ASCO and EHA results, along with regulatory milestones such as FDA Priority Review for a TEVIMBRA based regimen, indicate more potential indications for existing drugs, which can be important for long term earnings. At the same time, investors need to weigh a high P/E multiple, reliance on a few key products, elevated funding risk, and insider selling. In a market where investors are rotating toward essential healthcare, the key question is whether BeOne’s growth, pipeline and margins justify those risks and current expectations.

BeOne Medicines’ blockbuster drugs and late stage cancer pipeline may be masking what really matters for long term holders. Review the 4 key rewards and 1 important warning sign to see what could quietly reshape the story next.

Alnylam Pharmaceuticals (ALNY)

Overview: Alnylam Pharmaceuticals is a Cambridge based biotech company focused on developing and selling RNA interference therapies that target the genetic drivers of rare and serious diseases, with commercial products for conditions such as amyloidosis, hypercholesterolemia, hemophilia, and several liver and metabolic disorders, alongside an extensive late stage pipeline.

Operations: Alnylam Pharmaceuticals generates about US$4.3b from RNAi therapeutics, with around US$2.6b from the United States, US$0.7b from Europe, and roughly US$0.3b from the rest of the world.

Market Cap: US$42.9b

Alnylam Pharmaceuticals sits at the intersection of two themes investors are watching: a tilt toward healthcare as AI heavy tech valuations stretch, and demand for treatments that directly address high need diseases. The company already earns revenue from a portfolio of RNAi drugs and is advancing a broad pipeline across cardiology, neurology, and metabolic disorders. Recent AI partnerships aim to speed drug discovery and sharpen commercial execution. At the same time, a high P/E multiple, reliance on its TTR franchise, and a debt funded balance sheet mean expectations are demanding and setbacks could be painful. For investors screening healthcare stocks, the key issue is whether Alnylam’s RNAi platform and global expansion make the current valuation reasonable in a volatile market.

Alnylam Pharmaceuticals is being priced as if its RNAi platform can continue scaling, but the key question is how durable that outlook appears when you consider the full financials and pipeline together. Read the analysis report for Alnylam Pharmaceuticals for the one factor that could tilt the risk reward balance next.

Insmed (INSM)

Overview: Insmed is a Bridgewater, New Jersey based biopharma company focused on treatments for serious and rare diseases, including approved therapy ARIKAYCE for difficult lung infections and a broad pipeline targeting bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and other hard to treat conditions.

Operations: Insmed generates about US$819.6m from therapies for patients with rare diseases, with roughly US$658.7m from the United States and US$160.8m from international markets.

Market Cap: US$24.5b

Insmed is drawing attention from healthcare investors because it already has revenue from rare disease treatments while advancing late stage programs such as brensocatib. These programs could reshape its earnings profile if launches and label expansions progress as planned. At the same time, the company remains loss making, relies on external funding, and has seen insider selling and index removals. These factors highlight execution and financing risks if clinical or regulatory timelines slip. With analysts projecting strong long term growth and a DCF value that is currently indicated as being well above the current share price, the key consideration is how comfortable you are with the trade off between potential benefits from a respiratory and gene therapy portfolio and the financial and regulatory hurdles that still stand in the way.

Insmed’s rare disease portfolio and late stage respiratory and gene therapy programs could be accelerating into something bigger, yet the real inflection point might hide in the analyst forecasts for Insmed investors rarely factor in fully.

The three healthcare stocks covered here are only a starting point, as the full Healthcare Sector Stocks screener highlights 9 more companies with equally compelling narratives around pharmaceuticals, healthcare services, and medical devices. Use Simply Wall St to identify and analyze the specific catalysts and storylines that matter to you, so you can focus on the healthcare stocks that best align with your highest conviction ideas.

Take Control of Your Investment Journey

If BeOne Medicines or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Healthcare?

Some stocks are building quiet breakout momentum while the crowd stays focused elsewhere. Spot the ones still under the radar for now, before information goes stale and get in early.

• Target cash generative businesses that still trade at compressed valuations by scanning our curated 44 high quality undervalued stocks before the next leg of interest builds and prices move.
• Ride the next wave of automation demand by zeroing in on hand picked 30 robotics and automation stocks positioned for structural shifts in manufacturing and logistics while this theme is still forming.
• Position ahead of the next infrastructure upgrade cycle by reviewing a pre filtered 35 power grid technology and infrastructure stocks that focuses on companies tied to essential energy and grid resilience projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.